Symbols

INFU

Infusystem·AMEX

--(--)

INFU fundamentals

INFU Q4 2025 Earnings

Infusystem (INFU) released its earnings on Feb 24, 2026: revenue was 36.23M (YoY +7.04%), missed estimates; EPS was 0.1 (YoY +150.00%), beat estimates.

Revenue / YoY

36.23M

+7.04%

EPS / YoY

0.1

+150.00%

Report date

Feb 24, 2026

INFU Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 net revenue up 7% YoY to $36.2 million; full-year adjusted EBITDA expanded 24% to $31.5 million.
Strategic Wins: Wound Care revenue surged 160% with pneumatic compression devices; ERP upgrade to cut costs by $2 million annually.
Margin Strength: Gross margin improved to 56.1%, with EBITDA margin in mid-20s for 2026.
Shareholder Returns: Retired 1.3 million shares in 2025, reducing net debt by 30% YoY.
Growth Drivers: 6-8% revenue growth in 2026, fueled by Wound Care and new DME products like ChemoMouthpiece.

Earnings

EPS

Revenue

Revenue & Expenses

INFU has released its 2025 Q4 earnings report, with revenue of 36.23M, reflecting a YoY change of 7.04%, and net profit of 2.04M, showing a YoY change of 118.22%. The Sankey diagram below clearly presents INFU's revenue sources and cost distribution.

Key Indicators

Infusystem (INFU) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Infusystem (INFU)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Infusystem (INFU)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Infusystem (INFU)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown